Biogen scraps Alzheimer drug trials, wiping US$17 billion off its market value

📆 21/03/2019 19:28:00
📰 ChannelNewsAsia

⏱ Reading Time:
22 sec. here
2 min. at publisher
📊 Quality Score:
News: 12%
Publisher: 66%

Italia Notizia Notizia

Italia Ultime Notizie,Italia Notizie

Biogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer's drug, they said Thursday, marking the latest setback for ...

REUTERS: Biogen and partner Eisai Co Ltd are ending two late-stage trials for the experimental Alzheimer's drug aducanumab, in a setback to efforts to find treatments for the disease and for Biogen's stock, which lost more than US$17 billion of its value on Thursday.

Shares of Biogen sank 27 percent to US$233.98 in U.S. morning trading, its largest drop since Aug. 1, 2008 when it fell 28 percent. Japanese markets were closed for a national holiday. The trials ended just two weeks after Eisai's chief executive had expressed confidence in the drug."I believe we have already gone through the riskiest stage," Haruo Naito had said at a news briefing earlier this month.

Scrivi un Commento

Abbiamo riassunto questa notizia in modo che tu possa leggerla velocemente. Se sei interessato alla notizia puoi leggere il testo completo qui. Leggi di più:

Italia Ultime Notizie, Italia Notizie

Similar News:Puoi anche leggere notizie simili a questa che abbiamo raccolto da altre fonti di notizie.

Biogen scraps two Alzheimer drug trials, wipes US$18 billion from market valueBiogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer's drug, they said Thursday, marking the latest setback for ...
Fonte: ChannelNewsAsia - 🏆 6. / 66 Leggi di più »